Abstract
The aim of this study was to investigate the role of biopyrrins in the inflammatory-oxidative process in moderate-severe atopic dermatitis (AD). Furthermore, the study proposed to investigate the ability of biotechnological therapy with dupilumab to influence their concentration and action. For this purpose, 25 adult patients with moderate-severe AD, and 15 healthy control subjects, matched by sex and age, were enrolled. Morning urine samples were collected from all study participants. For AD patients, a collection was planned before to start therapy with dupilumab, after 8, 16 and 52 weeks of treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
